» Articles » PMID: 37851136

Unlocking Therapeutic Potential of Trigonelline Through Molecular Docking As a Promising Approach for Treating Diverse Neurological Disorders

Overview
Journal Metab Brain Dis
Publisher Springer
Specialties Endocrinology
Neurology
Date 2023 Oct 18
PMID 37851136
Authors
Affiliations
Soon will be listed here.
Abstract

Neurological disorders pose significant challenges in terms of treatment options, necessitating the exploration of novel therapeutic approaches. Trigonelline, a naturally occurring alkaloid found in various plants, has emerged as a potential treatment option. It has also been reported that trigonelline is involved in several pathways like; Oxidative Stress and Antioxidant, Inflammatory, Neuroprotection and Neurotrophic, Mitochondrial Function and Energy Metabolism. This study aims to investigate the therapeutic potential of trigonelline for diverse neurological disorders using a molecular docking approach. Molecular docking simulations were performed to predict the binding affinity and interaction between trigonelline and target proteins implicated in neurological disorders. The structural requirements for effective binding were also explored. The molecular docking results revealed strong binding interactions and favorable binding affinities between trigonelline and the target proteins involved in diverse neurological disorders like Alzheimer's disease, Parkinson's disease, epilepsy, and depression etc. The predicted binding modes provided insights into the key molecular interactions governing the ligand-protein complexes. The findings suggest that trigonelline holds promise as a therapeutic approach for several neurological disorders. The molecular docking approach employed in this study provides a valuable tool for rational drug design and optimization of trigonelline-based compounds. Further experimental validation and preclinical studies are warranted to confirm the efficacy and safety of trigonelline as a potential treatment option, paving the way for the development of more effective and targeted therapies for neurological disorders.

Citing Articles

Trigonelline as an anticonvulsant agent: mechanistic insights into NMDA receptor expression and oxidative stress balance.

Kabiri-Samani N, Amini-Khoei H, Rahimi-Madiseh M, Sureda A, Lorigooini Z Sci Rep. 2024; 14(1):14239.

PMID: 38902338 PMC: 11189925. DOI: 10.1038/s41598-024-65301-z.


Pharmacological Activities, Therapeutic Effects, and Mechanistic Actions of Trigonelline.

Nguyen V, Taine E, Meng D, Cui T, Tan W Int J Mol Sci. 2024; 25(6).

PMID: 38542359 PMC: 10970276. DOI: 10.3390/ijms25063385.

References
1.
Ahmad S, Azhar A, Tikmani P, Rafique H, Khan A, Mesiya H . A randomized clinical trial to test efficacy of chamomile and saffron for neuroprotective and anti-inflammatory responses in depressive patients. Heliyon. 2022; 8(10):e10774. PMC: 9547202. DOI: 10.1016/j.heliyon.2022.e10774. View

2.
Ahmad S, Rafiq H, Khan A, Tikmani P, Batool Z, Tabassum S . Ameliorative effects of half-dose saffron and chamomile combination on Psycho-endocrinological changes in a diabetic murine model. PLoS One. 2022; 17(10):e0276236. PMC: 9612524. DOI: 10.1371/journal.pone.0276236. View

3.
Ahmad S, Ahmed S, Khan A, Wasim M, Tabassum S, Haider S . Natural remedies for Alzheimer's disease: A systematic review of randomized controlled trials. Metab Brain Dis. 2022; 38(1):17-44. DOI: 10.1007/s11011-022-01063-9. View

4.
Arlt A, Sebens S, Krebs S, Geismann C, Grossmann M, Kruse M . Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. 2012; 32(40):4825-35. DOI: 10.1038/onc.2012.493. View

5.
Berman H, Battistuz T, Bhat T, Bluhm W, Bourne P, Burkhardt K . The Protein Data Bank. Acta Crystallogr D Biol Crystallogr. 2002; 58(Pt 6 No 1):899-907. DOI: 10.1107/s0907444902003451. View